Connor MJ, Khoo V, Watson V, Ahmed HU. Radical treatment without cure: decision-making in oligometastatic prostate cancer. Eur Urol. 2021 Apr;79(4):558-60. doi: 10.1016/j.eururo.2021.01.029
Chambers TM, Agopian AJ, Lewis RA, Langlois PH, Danysh HE, Weber KA, Shaw GM, Mitchell LE, Lupo PJ. Epidemiology of anophthalmia and microphthalmia: prevalence and patterns in Texas, 1999-2009. Am J Med Genet A. 2018 Sep;176(9):1810-8. doi: 10.1002/ajmg.a.40352
Ensor CR, Iasella CJ, Harrigan (Zhang) KM, Morrell MR, Moore CA, Shigemura N, Zeevi A, McDyer JF, Venkataramanan R. Increasing tacrolimus time-in-therapeutic range is associated with superior one-year outcomes in lung transplant recipients. Am J Transplant. 2018 Jun;18(6):1527-33. doi: 10.1111/ajt.14723
Wheeler A, Raspa M, Bann C, Bishop E, Hessl D, Sacco P, Bailey DBJr. Anxiety, attention problems, hyperactivity, and the aberrant behavior checklist in fragile x syndrome. Am J Med Genet A. 2014 Jan;164A(1):141-55. doi: 10.1002/ajmg.a.36232
DiBenedetti DB, Gondek K, Sagnier PP, Kubin M, Keininger D, Marquis P. The treatment satisfaction scale: a multidimensional instrument for the assessment of treatment satisfaction for erectile dysfunction patients and their partners. Eur Urol. 2005 Sep 1;48(3):503-11.
Rivero E, Varas-Lorenzo C, Maguire AR, Eisen HJ, Pedersen TR, Nashan B, Elkammas E. 10-Year predicted probability of coronary heart disease in renal transplant recipients treated with everolimus or mmf. Poster presented at the American Transplant Congress; April 2002. Washington, DC. [abstract] Am J Transplant. 2002; 2(Suppl 3):418.
Overland GB, Vatten L, Rhodes T, DeMuro C, Jacobsen G, Vada K, Angelsen A, Girman CJ. Lower urinary tract symptoms, prostate volume and uroflow in Norwegian community men. Eur Urol. 2001 Jan 1;39(1):36-41.